STEPHEN YENZEN LAI to Protein Kinase Inhibitors
This is a "connection" page, showing publications STEPHEN YENZEN LAI has written about Protein Kinase Inhibitors.
Connection Strength
0.442
-
A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab. 2021 09 27; 106(10):2962-2978.
Score: 0.259
-
Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol. 2024 Sep 01; 10(9):1264-1271.
Score: 0.079
-
Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck. 2014 Mar; 36(3):375-84.
Score: 0.036
-
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene. 2005 Jun 23; 24(27):4442-9.
Score: 0.021
-
Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol. 2024; 15:1369780.
Score: 0.019
-
Molecular mechanisms of resistance to kinase inhibitors and redifferentiation in thyroid cancers. Endocr Relat Cancer. 2022 11 01; 29(11):R173-R190.
Score: 0.017
-
Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 2013 Aug 27; 11:198.
Score: 0.009